As clinical FTO inhibitors are being developed for the treatment of obesity and cancer, our study provides preclinical rationale for further investigations into the efficacy and safety of these inhibitors for ccRCC treatment. This evidence concerns the gene FTO and nonpapillary renal cell carcinoma.